Home › Companies › Adaptimmune Therapeutics › 2024-2025
At Adaptimmune Therapeutics's shareholder meeting held May 29, 2025, in the 2024-2025 proxy season, 58 asset managers reported how they voted in their SEC Form N-PX filings, covering 265 separate fund positions. Their filings are grouped here into 14 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Adaptimmune Therapeutics's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Adaptimmune Therapeutics’s Form 8-K, filed May 29, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 29, 2025: 12 items on Adaptimmune Therapeutics’s Form 8-K, filed May 29, 2025: 12 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore Adaptimmune Therapeutics in the interactive database Compare manager voting policies
These tallies are Adaptimmune Therapeutics’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Ordinary Resolution to re-elect Dr. Ali Behbahani as a Director | 764,682,690 | 48,432,554 | 5,854,942 | -- | 766,066,516 | 94% | Not verified | — |
| Ordinary Resolution to re -elect Mr. John Furey as a Director | 793,576,104 | 19,443,008 | 5,951,074 | -- | 766,066,516 | 98% | Not verified | — |
| Ordinary Resolution to re -elect Mr. Adrian Rawcliffe as a Director | 792,968,070 | 20,102,708 | 5,899,408 | -- | 766,066,516 | 98% | Not verified | — |
| Ordinary Resolution to re-appoint KPMG LLP as auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders | 801,723,288 | 13,615,706 | 3,631,192 | -- | 766,066,516 | 98% | Not verified | — |
| Ordinary Resolution to authorize the Audit Committee to determine the Company's auditors' remuneration for the fiscal year ending December 31, 2025 | 800,455,908 | 14,664,992 | 3,849,286 | -- | 766,066,516 | 98% | Not verified | — |
| Ordinary Resolution to adopt the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2024 | 799,861,724 | 11,592,456 | 7,516,006 | -- | 766,066,516 | 99% | Not verified | — |
| Ordinary Resolution to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024 | 788,416,380 | 23,994,566 | 6,559,240 | -- | 766,066,516 | 97% | Not verified | — |
| Ordinary Resolution to receive and approve the Company's U.K. statutory Directors' remuneration report for the year ended December 31, 2024 | 791,717,832 | 19,808,270 | 7,444,084 | -- | 766,066,516 | 98% | Not verified | — |
| Ordinary Resolution to approve the rules of the Adaptimmune Therapeutics plc 2025 Employee Share Option Scheme, which, if approved, will take effect upon the conclusion of the Annual General Meeting | 763,924,788 | 51,678,788 | 3,366,610 | -- | 766,066,516 | 94% | Not verified | — |
| Ordinary Resolution to approve the rules of the Adaptimmune Therapeutics plc 2025 Non-Employee Share Option Scheme, which, if approved, will take effect upon the conclusion of the Annual General Meeting | 762,451,002 | 52,993,460 | 3,525,724 | -- | 766,066,516 | 94% | Not verified | — |
| Ordinary Resolution to a uthorize the Directors , in accordance with section 551 of the U.K. Companies Act 2006 (the "2006 Act"), to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares | 765,489,960 | 43,937,328 | 9,542,898 | -- | 766,066,516 | 95% | Not verified | — |
| Special Resolution to empower the Directors to allot equity securities for cash pursuant to section 570(1) of the 2006 Act as if section 561(1) of the 2006 Act did not apply to such allotment | 766,123,566 | 45,977,580 | 6,869,040 | -- | 766,066,516 | 94% | Not verified | — |
Source: Adaptimmune Therapeutics, Form 8-K, filed with the SEC on May 29, 2025 — read the filing on EDGAR.
Each item below shows how the 58 asset managers that disclosed a Adaptimmune Therapeutics vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Adaptimmune Therapeutics’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect as a director, Adrian Rawcliffe, who retires by rotation in accordance with the Articles of Association.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 3 – Ordinary Resolution to re -elect Mr. Adrian Rawcliffe as a Director:”): 792,968,070 for, 20,102,708 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
94% Majority: yes · of votes cast
Description as filed by funds: To re-elect as a director, Ali Behbahani, who retires by rotation in accordance with the Articles of Association.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 1 – Ordinary Resolution to re-elect Dr. Ali Behbahani as a Director:”): 764,682,690 for, 48,432,554 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 421,299 | 0 | 0 | Against |
| SEI | 0 | 246,744 | 0 | 0 | Against |
| Fidelity | 0 | 186,117 | 0 | 0 | Against |
| Northern Trust | 0 | 16,891 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 8,118 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 4,721 | 0 | 0 | Against |
| Guggenheim | 0 | 273 | 0 | 0 | Against |
98% Majority: yes · of votes cast
Description as filed by funds: To re-elect as a director, John Furey, who retires by rotation in accordance with the Articles of Association.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 2 – Ordinary Resolution to re -elect Mr. John Furey as a Director:”): 793,576,104 for, 19,443,008 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To authorize the Directors under Section 551 of the U.K. Companies Act 2006 (the "2006 Act") to allot shares or to grant rights to subscribe for or to convert any security into shares.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 11 – Ordinary Resolution to a uthorize the Directors , in accordance with section 551 of the U.K. Companies Act 2006 (the "2006 Act"), to allot shares in the Company or to grant rights to subscribe for or to c”): 765,489,960 for, 43,937,328 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 432,861 for, 451,302 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 421,299 | 0 | 0 | Against |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 16,891 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 8,118 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 4,721 | 0 | 0 | Against |
| Guggenheim | 0 | 273 | 0 | 0 | Against |
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To empower the Directors to allot equity securities for cash pursuant to Section 570(1) of the 2006 Act as if Section 561(1) of the 2006 Act did not apply to that allotment.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 12 – Special Resolution to empower the Directors to allot equity securities for cash pursuant to section 570(1) of the 2006 Act as if section 561(1) of the 2006 Act did not apply to such allotment:”): 766,123,566 for, 45,977,580 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 432,861 for, 451,302 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 421,299 | 0 | 0 | Against |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 16,891 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 0 | 8,118 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 4,721 | 0 | 0 | Against |
| Guggenheim | 0 | 273 | 0 | 0 | Against |
99% Majority: yes · of votes cast
Description as filed by funds: To adopt the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024 and to note that the Directors do not recommend the payment of any dividend for the year ended December 31, 2024.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 6 – Ordinary Resolution to adopt the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2024 and to note that the Directors do not recommend the payment of any dividend for the y”): 799,861,724 for, 11,592,456 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
29% of fund votes cast · no official result
Description as filed by funds: To approve our 2025 employee share option scheme, which, if approved, will take effect upon the conclusion of the Annual General Meeting.
The 7 asset managers below reported 254,862 for, 629,301 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 421,299 | 0 | 0 | Against |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 0 | 186,117 | 0 | 0 | Against |
| Northern Trust | 0 | 16,891 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 4,721 | 0 | 0 | Against |
| Guggenheim | 0 | 273 | 0 | 0 | Against |
94% Majority: yes · of votes cast
Description as filed by funds: To approve our 2025 non-employee share option scheme, which, if approved, will take effect upon the conclusion of the Annual General Meeting.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 10 – Ordinary Resolution to approve the rules of the Adaptimmune Therapeutics plc 2025 Non-Employee Share Option Scheme, which, if approved, will take effect upon the conclusion of the Annual General Meeting:”): 762,451,002 for, 52,993,460 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 254,862 for, 629,301 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 0 | 421,299 | 0 | 0 | Against |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 0 | 186,117 | 0 | 0 | Against |
| Northern Trust | 0 | 16,891 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 4,721 | 0 | 0 | Against |
| Guggenheim | 0 | 273 | 0 | 0 | Against |
Combines 7 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 7 – Ordinary Resolution to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2024:”): 788,416,380 for, 23,994,566 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 108,058,772 for, 6,490,164 against, 10,617 1 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 27,404,070 | 0 | 0 | 0 | For |
| Long Focus Capital Management, LLC | 23,756,687 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 22,569,885 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 17,082,615 | 0 | 0 | 0 | For |
| Rathbones Group PLC | 0 | 6,372,000 | 0 | 0 | Against |
| MPM ASSET MANAGEMENT LLC | 4,809,677 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 4,411,821 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 2,483,468 | 0 | 0 | 0 | For |
| Impresa Management LLC | 1,578,783 | 0 | 0 | 0 | For |
| Renaissance | 1,554,207 | 0 | 0 | 0 | For |
| State Street | 844,698 | 0 | 0 | 0 | For |
| SEI | 493,488 | 0 | 0 | 0 | For |
| Fidelity | 305,202 | 0 | 0 | 0 | For |
| VIRGINIA RETIREMENT SYSTEMS ET Al | 104,787 | 0 | 0 | 0 | For |
| Clear Harbor Asset Management, LLC | 90,000 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 88,000 | 0 | 0 | 0 | For |
| Invesco | 78,031 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 67,032 | 0 | 0 | 0 | For |
| State of New Jersey Common Pension Fund D | 54,718 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 52,431 | 0 | 0 | Against |
| Regime de rentes du Mouvement Desjardins | 0 | 52,431 | 0 | 0 | Against |
| Northern Trust | 47,600 | 0 | 0 | 0 | For |
| BlackRock | 44,822 | 0 | 0 | 0 | For |
| Two Sigma | 36,959 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 35,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
100% of fund votes cast · no official result
Description as filed by funds: To approve, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of the Company's named executive officers.
The 51 asset managers below reported 11,052 for, 6,372,000 abstained, 60,157,729 1 year, 22,569,885 unknown. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 0 | 0 | 0 | 0 | -- |
| Two Seas Capital LP | 0 | 0 | 0 | 0 | -- |
| NEA Management Company, LLC | 0 | 0 | 0 | 0 | -- |
| Rathbones Group PLC | 0 | 0 | 6,372,000 | 0 | Abstain |
| MPM ASSET MANAGEMENT LLC | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| VIRGINIA RETIREMENT SYSTEMS ET Al | 0 | 0 | 0 | 0 | -- |
| Clear Harbor Asset Management, LLC | 0 | 0 | 0 | 0 | -- |
| CAPTRUST FINANCIAL ADVISORS | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| State of New Jersey Common Pension Fund D | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| BROWN ADVISORY INC | 0 | 0 | 0 | 0 | -- |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 0 | 0 | 0 | -- |
| Rhumbline | 10,617 | 0 | 0 | 0 | For |
| KORNITZER CAPITAL MANAGEMENT INC /KS | 0 | 0 | 0 | 0 | -- |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 0 | -- |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To approve our U.K. statutory directors' remuneration report for the year ended December 31, 2024
Adaptimmune Therapeutics’s own tally for this item (“Resolution 8 – Ordinary Resolution to receive and approve the Company's U.K. statutory Directors' remuneration report for the year ended December 31, 2024:”): 791,717,832 for, 19,808,270 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 27,404,070 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 52,431 | 0 | 0 | Against |
| BlackRock | 44,822 | 0 | 0 | 0 | For |
| JPMorgan | 8,239 | 0 | 0 | 0 | For |
| MERCER GLOBAL ADVISORS INC /ADV | 1,003 | 0 | 0 | 0 | For |
| Chicago Partners Investment Group LLC | 921 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 27,459,055 for, 52,431 against.
— of fund votes cast · no official result
The 3 asset managers below reported 60,684 1 year.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Desjardins Global Asset Management Inc. | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| TD Waterhouse Canada Inc. | 0 | 0 | 0 | 0 | -- |
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To authorize the Audit Committee to determine our auditors' remuneration for the fiscal year ending December 31, 2025.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 5 – Ordinary Resolution to authorize the Audit Committee to determine the Company's auditors' remuneration for the fiscal year ending December 31, 2025:”): 800,455,908 for, 14,664,992 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
98% Majority: yes · of votes cast
Description as filed by funds: To re-appoint KPMG LLP as auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders.
Adaptimmune Therapeutics’s own tally for this item (“Resolution 4 – Ordinary Resolution to re-appoint KPMG LLP as auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders:”): 801,723,288 for, 13,615,706 against, per its Form 8-K filed May 29, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 884,163 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 421,299 | 0 | 0 | 0 | For |
| SEI | 246,744 | 0 | 0 | 0 | For |
| Fidelity | 186,117 | 0 | 0 | 0 | For |
| Northern Trust | 16,891 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 8,118 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 4,721 | 0 | 0 | 0 | For |
| Guggenheim | 273 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 1,590,309,546 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 0.03% |
| 2 | SEI | 0.02% |
| 3 | Fidelity | 0.01% |
| 4 | Northern Trust | <0.01% |
| 5 | MASTER INVESTMENT PORTFOLIO | <0.01% |
| 6 | Blackstone Alternative Investment Funds | <0.01% |
| 7 | Guggenheim | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | EcoR1 Capital, LLC | 1.72% |
| 2 | Long Focus Capital Management, LLC | 1.49% |
| 3 | Two Seas Capital LP | 1.42% |
| 4 | NEA Management Company, LLC | 1.07% |
| 5 | Rathbones Group PLC | 0.40% |
| 6 | MPM ASSET MANAGEMENT LLC | 0.30% |
| 7 | MPM BioImpact LLC | 0.28% |
| 8 | Rock Springs Capital Management LP | 0.16% |
| 9 | Impresa Management LLC | 0.10% |
| 10 | Renaissance | 0.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Long Focus Capital Management, LLC | 7.73% | DEF14A |
| Ali Behbahani, M.D. | 6.64% | DEF14A |
| Two Seas Capital L.P. | 5.60% | DEF14A |
| BAILLIE GIFFORD & CO | 4.46% | 13G |
| EcoR1 Capital, LLC | 4.15% | 13G |
| Adrian Rawcliffe | 1.48% | DEF14A |
| Garry Menzel | 0.96% | DEF14A |
| William Bertrand | 0.72% | DEF14A |
| Gavin Wood | 0.51% | DEF14A |
| John Lunger | 0.50% | DEF14A |
Percentages above are of 1,590,309,546 shares outstanding, as reported by Adaptimmune Therapeutics on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Adaptimmune Therapeutics’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Adaptimmune Therapeutics proxy season coverage: 2023-2024 · 2024-2025 (this page).
proxyvotesnow.com, “Adaptimmune Therapeutics (ADAPY) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/adaptimmune-therapeutics-plc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.